Amgen (NASDAQ:AMGN) Downgraded by Wall Street Zen to “Hold”

Posted by Brenda Bartman on Oct 11th, 2026

Wall Street Zen downgraded shares of Amgen (NASDAQ:AMGN – Free Report) from a buy rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

AMGN has been the topic of several other reports. Barclays upped their target price on Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Oppenheimer reissued an “outperform” rating on shares of Amgen in a research note on Wednesday, September 23rd. Wells Fargo & Company raised their price objective on shares of Amgen from $400.00 to $435.00 and gave the company an “equal weight” rating in a research report on Friday, September 4th. Truist Financial lifted their target price on shares of Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, TD Cowen lifted their target price on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $389.71.

Get Our Latest Stock Report on Amgen

Amgen Trading Up 1.8%

Shares of NASDAQ:AMGN opened at $414.87 on Friday. The firm has a fifty day moving average of $412.94 and a two-hundred day moving average of $372.18. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen has a 12-month low of $288.00 and a 12-month high of $447.03. The firm has a market capitalization of $224.29 billion, a P/E ratio of 25.78, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the business posted $6.02 earnings per share. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts expect that Amgen will post 22.94 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amgen

Several hedge funds have recently modified their holdings of the business. Marquette Asset Management LLC increased its position in shares of Amgen by 78.4% in the third quarter. Marquette Asset Management LLC now owns 330 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 145 shares during the last quarter. Friday Financial acquired a new position in Amgen during the third quarter valued at approximately $208,000. Castleview Partners LLC boosted its position in Amgen by 5.8% during the third quarter. Castleview Partners LLC now owns 11,160 shares of the medical research company’s stock valued at $4,704,000 after purchasing an additional 608 shares during the last quarter. Stokes Capital Advisors LLC grew its stake in Amgen by 187.8% in the third quarter. Stokes Capital Advisors LLC now owns 8,811 shares of the medical research company’s stock valued at $3,714,000 after purchasing an additional 5,750 shares in the last quarter. Finally, Mirador Capital Partners LP grew its stake in Amgen by 16.5% in the third quarter. Mirador Capital Partners LP now owns 1,642 shares of the medical research company’s stock valued at $692,000 after purchasing an additional 232 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

Positive Sentiment: UBS upgraded Amgen to Buy and raised its price target to $470 from $430, implying further upside from the reported $414.87 share price. The upgrade is the clearest near-term catalyst behind the stock’s strength. Benzinga analyst upgrade report
Positive Sentiment: Amgen announced a head-to-head Phase 3 trial for its monthly diabetes drug candidate against semaglutide. Success could strengthen the company’s position in the highly competitive GLP-1 market and provide a significant future growth opportunity, although clinical and commercial risks remain. Amgen monthly diabetes trial article
Positive Sentiment: Cantor Fitzgerald raised its Amgen price target to $440 from $400, signaling improved expectations despite maintaining a Hold rating. Cantor Fitzgerald price target report

About Amgen

(Get Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.